Navigation Links
Hope For Patients With Prostate Cancer

Researchers say new research might help extend the survival for men with advanced prostate cancer.In one study, researchers studied more // than 600 men with hormone-refractory prostate cancer. About half of the men were treated with the drug combination docetaxel and estramustine while the other half was treated with standard care, which is mitoxantrone and prednisone.

Researchers found improved survival among the men who received the docetaxel/estramustine treatment and it was also found that there was a greater significance in survival rates . Men in the docetaxel/estramustine group were found to have about a 20-percent reduced risk of death.Thus researchers say that this shows that docetaxel can effectively treat [this type of] prostate cancer. Side effects include nausea, vomiting and infections.

In a second study, researchers studied men with prostate cancer who received one of three treatments: docetaxel plus prednisone every week; a higher dose of docetaxel plus prednisone every three weeks, or mitoxantrone plus prednisone weekly. Researchers say survival among the men who received the docetaxel/prednisone treatment every three weeks was significantly greater (18.9 months) than the other two treatment regimens (17.4 months and 16.5 months respectively). Results show there was also a greater drop in PSA level among men in this treatment group, as well as less pain and improved quality of life.Thus researchers say it is indeed a reason for celebration and also optimism as it can serve as platform for further research.
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... ... 2017 , ... The non-profit Seafood Nutrition Partnership (SNP) ... the Science Symposium in partnership with the Global Organization for EPA and DHA ... a forum for global leaders in human nutrition to outline the latest consensus ...
(Date:8/22/2017)... ... August 22, 2017 , ... Western North ... at a popular international aesthetics conference for medical professionals about the positive impact ... health and his growing practice. , Dr. George K. Ibrahim shared ...
(Date:8/22/2017)... ... 22, 2017 , ... Nurses at Apple Rehab Watch Hill , a ... training and certification in Closed Pulse Irrigation™ (CPI) for wound care. This ... the Centers for Medicare and Medicaid Services, to have a CPI machine that will ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... story of child abuse and neglect, and the struggles faced while hoping for ... the creation of published author, Judy Von Bernewitz, who spent 13 years working ...
(Date:8/22/2017)... ... August 22, 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating ... , As the stress of modern life continually makes more demands on time and ... artificial stimulants can trap people in vicious high/low cycles and can also cause long ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/11/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it will release its second quarter ... conference call at 9:00am ET. The Company will discuss ... its strategy and outlook for the remainder of 2017. The ... , Chief Executive Officer, and Zvi Ben-David , ...
(Date:8/8/2017)... TEL AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. ... and immunology, today reports its financial results for the ... and achievements during the second quarter 2017 and to ... on multiple clinical development programs for the Company,s lead ... Phase 3 pivotal study with BL-8040 as novel stem ...
Breaking Medicine Technology: